Xeltis, a Dutch American medical technology company, raised an additional 20.5 million euros. The technology is genuinely striking: artificial blood vessels and heart valves that are gradually replaced by the patient's own living tissue. The money is aimed squarely at advancing toward FDA approval and a US commercial launch.

I like this story precisely because it is not a billion dollar industrial headline. Most European companies I meet are not Siemens Energy or Prysmian. They are excellent, focused, and comparatively small, and they look at America and wonder where the entry point is for a company their size.

Here it is. For regulated products, the US path is capital, clinical evidence, and regulatory approval, in that order, over years. That is slow and it is expensive, and it is also a moat. Once you clear FDA and get reimbursement conversations moving, the American market pays for the patience.

The other thing worth copying is the structure. Xeltis is described as Dutch American, not Dutch with an American ambition. Building the US identity early, in the entity, the team, and the investor base, changes how American partners, hospitals, and regulators receive you.

So take the pair of lessons from the same week. Large industrials are buying and building their way into the United States. Smaller specialists are funding and qualifying their way in. Both are choosing to become part of the American market rather than a visitor to it.

Reference